Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pituitary Neoplasms | 52 | 2024 | 1313 | 7.420 |
Why?
|
Adenoma | 47 | 2024 | 2148 | 5.680 |
Why?
|
Pituitary ACTH Hypersecretion | 15 | 2024 | 178 | 3.100 |
Why?
|
Acromegaly | 14 | 2024 | 306 | 2.740 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 10 | 2023 | 63 | 2.590 |
Why?
|
Craniopharyngioma | 9 | 2023 | 277 | 2.580 |
Why?
|
Radiosurgery | 18 | 2024 | 1343 | 2.560 |
Why?
|
Hypopituitarism | 8 | 2022 | 248 | 2.180 |
Why?
|
Somatostatin | 6 | 2020 | 447 | 1.800 |
Why?
|
Neurosurgical Procedures | 12 | 2021 | 2056 | 1.060 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 6 | 2024 | 49 | 0.990 |
Why?
|
Human Growth Hormone | 9 | 2024 | 638 | 0.970 |
Why?
|
Serum Amyloid A Protein | 1 | 2024 | 127 | 0.930 |
Why?
|
Adrenocorticotropic Hormone | 10 | 2024 | 618 | 0.910 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2024 | 159 | 0.860 |
Why?
|
Hypothalamus | 3 | 2023 | 998 | 0.760 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2023 | 9278 | 0.730 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 2 | 2019 | 150 | 0.730 |
Why?
|
Microsurgery | 4 | 2021 | 796 | 0.690 |
Why?
|
Pro-Opiomelanocortin | 5 | 2024 | 140 | 0.680 |
Why?
|
Octreotide | 1 | 2020 | 153 | 0.680 |
Why?
|
Inflammasomes | 1 | 2024 | 532 | 0.650 |
Why?
|
Prolactinoma | 5 | 2023 | 113 | 0.650 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2019 | 454 | 0.640 |
Why?
|
Third Ventricle | 2 | 2016 | 74 | 0.630 |
Why?
|
Peptides, Cyclic | 1 | 2020 | 392 | 0.610 |
Why?
|
Endopeptidases | 2 | 2019 | 772 | 0.610 |
Why?
|
Infratentorial Neoplasms | 1 | 2019 | 98 | 0.600 |
Why?
|
Pituitary Gland | 9 | 2023 | 637 | 0.580 |
Why?
|
Amyloidosis | 1 | 2024 | 817 | 0.580 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 2017 | 47 | 0.570 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2016 | 44 | 0.550 |
Why?
|
Receptors, Somatostatin | 4 | 2024 | 136 | 0.550 |
Why?
|
Follicle Stimulating Hormone | 2 | 2017 | 725 | 0.550 |
Why?
|
Prion Diseases | 3 | 2022 | 98 | 0.530 |
Why?
|
Prions | 3 | 2022 | 179 | 0.520 |
Why?
|
Ependymoma | 1 | 2019 | 320 | 0.510 |
Why?
|
Skull Base Neoplasms | 3 | 2018 | 269 | 0.510 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2022 | 1928 | 0.500 |
Why?
|
Thyrotropin | 3 | 2015 | 832 | 0.490 |
Why?
|
Pituitary Hormones | 2 | 2013 | 182 | 0.430 |
Why?
|
Meningioma | 4 | 2020 | 1221 | 0.410 |
Why?
|
Cushing Syndrome | 4 | 2022 | 241 | 0.400 |
Why?
|
Treatment Outcome | 34 | 2024 | 64981 | 0.400 |
Why?
|
Zygoma | 1 | 2012 | 52 | 0.400 |
Why?
|
Frontal Bone | 1 | 2012 | 105 | 0.380 |
Why?
|
Hypophysectomy | 3 | 2020 | 114 | 0.370 |
Why?
|
Neoplasm, Residual | 4 | 2019 | 1008 | 0.340 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2009 | 87 | 0.330 |
Why?
|
Retrospective Studies | 28 | 2024 | 80345 | 0.330 |
Why?
|
Optic Nerve Diseases | 2 | 2012 | 342 | 0.320 |
Why?
|
Incidental Findings | 1 | 2013 | 698 | 0.310 |
Why?
|
Orbit | 1 | 2012 | 446 | 0.310 |
Why?
|
Receptors, Glucocorticoid | 2 | 2023 | 296 | 0.300 |
Why?
|
Adult | 48 | 2024 | 220007 | 0.300 |
Why?
|
Sphenoid Bone | 4 | 2021 | 177 | 0.300 |
Why?
|
Anesthesia | 1 | 2019 | 1584 | 0.300 |
Why?
|
Dacarbazine | 1 | 2010 | 560 | 0.290 |
Why?
|
Ligands | 4 | 2024 | 3276 | 0.290 |
Why?
|
Hormones | 3 | 2023 | 867 | 0.290 |
Why?
|
Decompression, Surgical | 2 | 2012 | 604 | 0.290 |
Why?
|
Temporal Bone | 1 | 2012 | 683 | 0.280 |
Why?
|
Humans | 92 | 2024 | 760613 | 0.280 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2010 | 618 | 0.270 |
Why?
|
Cranial Irradiation | 4 | 2020 | 391 | 0.270 |
Why?
|
Spinal Fractures | 2 | 2024 | 702 | 0.270 |
Why?
|
Female | 58 | 2024 | 391246 | 0.260 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8552 | 0.250 |
Why?
|
Dopamine Agonists | 3 | 2023 | 352 | 0.250 |
Why?
|
Middle Aged | 42 | 2024 | 220359 | 0.250 |
Why?
|
Pituitary Gland, Posterior | 2 | 2016 | 42 | 0.250 |
Why?
|
Male | 55 | 2024 | 359718 | 0.250 |
Why?
|
Prolactin | 3 | 2023 | 621 | 0.250 |
Why?
|
Granular Cell Tumor | 2 | 2016 | 48 | 0.240 |
Why?
|
Hydrocortisone | 6 | 2022 | 1803 | 0.240 |
Why?
|
Vision Disorders | 5 | 2018 | 1084 | 0.240 |
Why?
|
Chordoma | 2 | 2020 | 346 | 0.230 |
Why?
|
Salvage Therapy | 1 | 2010 | 1268 | 0.230 |
Why?
|
Postoperative Period | 4 | 2016 | 1818 | 0.210 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2023 | 60 | 0.210 |
Why?
|
PrPC Proteins | 1 | 2022 | 37 | 0.210 |
Why?
|
Italy | 2 | 2015 | 841 | 0.200 |
Why?
|
Sphenoid Sinus | 2 | 2016 | 99 | 0.190 |
Why?
|
Calreticulin | 1 | 2022 | 115 | 0.190 |
Why?
|
Thyroid Neoplasms | 1 | 2015 | 2332 | 0.190 |
Why?
|
Nelson Syndrome | 1 | 2021 | 20 | 0.190 |
Why?
|
Visual Pathways | 3 | 2024 | 534 | 0.190 |
Why?
|
Sella Turcica | 1 | 2021 | 118 | 0.180 |
Why?
|
Receptors, Somatotropin | 1 | 2020 | 58 | 0.180 |
Why?
|
Dexamethasone | 3 | 2023 | 1927 | 0.180 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13627 | 0.180 |
Why?
|
Neuronavigation | 1 | 2021 | 164 | 0.180 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39262 | 0.180 |
Why?
|
Craniotomy | 3 | 2021 | 741 | 0.170 |
Why?
|
Prognosis | 6 | 2020 | 29661 | 0.170 |
Why?
|
Luteinizing Hormone | 2 | 2017 | 820 | 0.170 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2021 | 187 | 0.170 |
Why?
|
Optic Chiasm | 2 | 2018 | 91 | 0.170 |
Why?
|
Organs at Risk | 1 | 2021 | 358 | 0.170 |
Why?
|
Aged | 23 | 2024 | 169143 | 0.160 |
Why?
|
Propensity Score | 2 | 2024 | 1926 | 0.160 |
Why?
|
Oxytocin | 1 | 2023 | 401 | 0.160 |
Why?
|
Fluorescence | 1 | 2021 | 751 | 0.160 |
Why?
|
History, 19th Century | 1 | 2021 | 720 | 0.160 |
Why?
|
Young Adult | 12 | 2023 | 58748 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 14 | 2023 | 36286 | 0.160 |
Why?
|
Adrenalectomy | 1 | 2021 | 348 | 0.160 |
Why?
|
Body Mass Index | 1 | 2016 | 12914 | 0.160 |
Why?
|
Calculi | 1 | 2019 | 49 | 0.160 |
Why?
|
Watchful Waiting | 1 | 2023 | 510 | 0.160 |
Why?
|
Empty Sella Syndrome | 1 | 2018 | 14 | 0.160 |
Why?
|
Encephalocele | 1 | 2019 | 135 | 0.150 |
Why?
|
Cell Differentiation | 1 | 2015 | 11481 | 0.150 |
Why?
|
Chondrosarcoma | 1 | 2020 | 296 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 612 | 0.130 |
Why?
|
Quality of Life | 6 | 2023 | 13308 | 0.130 |
Why?
|
Postoperative Complications | 10 | 2023 | 15679 | 0.130 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2016 | 89 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 464 | 0.130 |
Why?
|
Autoantigens | 1 | 2020 | 877 | 0.130 |
Why?
|
Cerebellum | 2 | 2022 | 1495 | 0.130 |
Why?
|
Ubiquitination | 1 | 2019 | 1008 | 0.120 |
Why?
|
alpha-Synuclein | 1 | 2021 | 749 | 0.120 |
Why?
|
Hypothyroidism | 3 | 2016 | 665 | 0.120 |
Why?
|
Vision, Ocular | 1 | 2018 | 454 | 0.120 |
Why?
|
Meningeal Neoplasms | 2 | 2020 | 1249 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 755 | 0.120 |
Why?
|
Thyroid Function Tests | 1 | 2015 | 289 | 0.120 |
Why?
|
Reoperation | 4 | 2023 | 4289 | 0.110 |
Why?
|
Corticotropin-Releasing Hormone | 4 | 2022 | 361 | 0.110 |
Why?
|
Cell Communication | 1 | 2021 | 1653 | 0.110 |
Why?
|
Consensus | 2 | 2020 | 3113 | 0.110 |
Why?
|
Cerebellar Neoplasms | 1 | 2019 | 586 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1504 | 0.110 |
Why?
|
History, 20th Century | 1 | 2021 | 2773 | 0.110 |
Why?
|
Medulloblastoma | 1 | 2019 | 678 | 0.110 |
Why?
|
Ultrasonography, Interventional | 1 | 2021 | 1501 | 0.110 |
Why?
|
Premenopause | 1 | 2017 | 1038 | 0.110 |
Why?
|
Adolescent | 13 | 2023 | 87809 | 0.110 |
Why?
|
Cranial Fossa, Posterior | 1 | 2013 | 135 | 0.110 |
Why?
|
Plasmacytoma | 1 | 2013 | 171 | 0.110 |
Why?
|
Azacitidine | 1 | 2014 | 334 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7475 | 0.100 |
Why?
|
Enzyme Activators | 1 | 2012 | 57 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1791 | 0.100 |
Why?
|
Monitoring, Intraoperative | 1 | 2019 | 942 | 0.100 |
Why?
|
Aminoimidazole Carboxamide | 1 | 2012 | 85 | 0.100 |
Why?
|
Ribonucleotides | 1 | 2012 | 114 | 0.100 |
Why?
|
Adenylate Kinase | 1 | 2012 | 102 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2864 | 0.100 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 192 | 0.100 |
Why?
|
Preoperative Care | 1 | 2020 | 2255 | 0.090 |
Why?
|
Vision Tests | 1 | 2012 | 158 | 0.090 |
Why?
|
Time Factors | 8 | 2020 | 40139 | 0.090 |
Why?
|
Autoantibodies | 1 | 2020 | 2119 | 0.090 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2010 | 83 | 0.090 |
Why?
|
Recombinant Proteins | 1 | 2020 | 6538 | 0.090 |
Why?
|
Dura Mater | 1 | 2012 | 290 | 0.090 |
Why?
|
Patient Care Team | 1 | 2020 | 2511 | 0.080 |
Why?
|
Mice, Knockout | 1 | 2024 | 14374 | 0.080 |
Why?
|
Hyperprolactinemia | 2 | 2016 | 123 | 0.080 |
Why?
|
Child | 9 | 2023 | 79799 | 0.080 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6831 | 0.080 |
Why?
|
Case-Control Studies | 4 | 2020 | 22052 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3598 | 0.070 |
Why?
|
Pediatrics | 1 | 2023 | 3586 | 0.070 |
Why?
|
Hypogonadism | 1 | 2013 | 801 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2013 | 6238 | 0.070 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2011 | 699 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2010 | 586 | 0.070 |
Why?
|
Ergolines | 1 | 2006 | 57 | 0.070 |
Why?
|
Optic Nerve | 1 | 2009 | 567 | 0.070 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22020 | 0.070 |
Why?
|
Prospective Studies | 5 | 2023 | 54306 | 0.060 |
Why?
|
Endothelin-1 | 1 | 2007 | 302 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58980 | 0.060 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18137 | 0.060 |
Why?
|
Cell Proliferation | 3 | 2017 | 10442 | 0.060 |
Why?
|
Magnetic Resonance Angiography | 1 | 2012 | 1431 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4783 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2019 | 6130 | 0.060 |
Why?
|
Visual Fields | 1 | 2011 | 1054 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2020 | 8985 | 0.060 |
Why?
|
Remission Induction | 1 | 2010 | 2392 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 10755 | 0.060 |
Why?
|
Cohort Studies | 3 | 2024 | 41337 | 0.060 |
Why?
|
Mice | 4 | 2024 | 81209 | 0.060 |
Why?
|
Recurrence | 2 | 2009 | 8483 | 0.060 |
Why?
|
Obesity | 2 | 2023 | 12919 | 0.060 |
Why?
|
Intracranial Hypertension | 1 | 2006 | 193 | 0.050 |
Why?
|
Antibodies | 2 | 2022 | 2421 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6544 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8512 | 0.050 |
Why?
|
Visual Acuity | 1 | 2012 | 2643 | 0.050 |
Why?
|
Animals | 6 | 2024 | 167960 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12628 | 0.050 |
Why?
|
HMGA2 Protein | 1 | 2002 | 102 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2013 | 12531 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6465 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9716 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2004 | 403 | 0.050 |
Why?
|
Anesthesia Recovery Period | 1 | 2002 | 155 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2007 | 3530 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 29957 | 0.050 |
Why?
|
Insulin | 2 | 2007 | 6596 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12159 | 0.040 |
Why?
|
Sheep | 1 | 2022 | 1441 | 0.040 |
Why?
|
Ribonucleoproteins | 1 | 2022 | 372 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2012 | 881 | 0.040 |
Why?
|
Thoracic Vertebrae | 1 | 2024 | 597 | 0.040 |
Why?
|
Acyltransferases | 1 | 2021 | 305 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 5 | 2019 | 20509 | 0.040 |
Why?
|
Labial Frenum | 1 | 2019 | 6 | 0.040 |
Why?
|
Hydrocephalus | 1 | 2006 | 763 | 0.040 |
Why?
|
Carcinoma | 1 | 2010 | 2331 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15286 | 0.040 |
Why?
|
Glucose | 3 | 2019 | 4350 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1722 | 0.040 |
Why?
|
Endoscopy | 2 | 2023 | 1838 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2942 | 0.040 |
Why?
|
Molecular Chaperones | 1 | 2022 | 752 | 0.040 |
Why?
|
Homozygote | 1 | 2022 | 1788 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 18413 | 0.040 |
Why?
|
Risk Factors | 2 | 2024 | 74333 | 0.040 |
Why?
|
Mammals | 1 | 2022 | 1131 | 0.040 |
Why?
|
Benchmarking | 1 | 2023 | 1044 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 21391 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11902 | 0.030 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2017 | 257 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2022 | 12968 | 0.030 |
Why?
|
Prevalence | 2 | 2024 | 15686 | 0.030 |
Why?
|
Lysosomes | 1 | 2021 | 920 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2019 | 1174 | 0.030 |
Why?
|
Trans-Activators | 1 | 2005 | 2860 | 0.030 |
Why?
|
Diabetes Insipidus | 1 | 2016 | 144 | 0.030 |
Why?
|
Gynecomastia | 1 | 2016 | 87 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10546 | 0.030 |
Why?
|
Skull | 1 | 2019 | 815 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1180 | 0.030 |
Why?
|
Brain | 2 | 2021 | 26951 | 0.030 |
Why?
|
RNA Interference | 1 | 2022 | 2846 | 0.030 |
Why?
|
Drosophila melanogaster | 1 | 2022 | 1710 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3442 | 0.030 |
Why?
|
Piperidines | 1 | 2002 | 1650 | 0.030 |
Why?
|
Heterozygote | 1 | 2020 | 2798 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9406 | 0.030 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2012 | 4 | 0.030 |
Why?
|
Proteome | 1 | 2022 | 1855 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11713 | 0.030 |
Why?
|
Ketoconazole | 1 | 2012 | 97 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2017 | 1204 | 0.020 |
Why?
|
Telomerase | 1 | 2017 | 747 | 0.020 |
Why?
|
Term Birth | 1 | 2012 | 140 | 0.020 |
Why?
|
Bone Density | 1 | 2024 | 3534 | 0.020 |
Why?
|
Abruptio Placentae | 1 | 2012 | 118 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4035 | 0.020 |
Why?
|
Homeostasis | 1 | 2021 | 3306 | 0.020 |
Why?
|
Heart Rate | 1 | 2002 | 4180 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 616 | 0.020 |
Why?
|
Gonadotropins | 1 | 2011 | 241 | 0.020 |
Why?
|
Survival Analysis | 1 | 2002 | 10185 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2018 | 2007 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2913 | 0.020 |
Why?
|
Recovery of Function | 1 | 2019 | 2985 | 0.020 |
Why?
|
Nerve Compression Syndromes | 1 | 2009 | 160 | 0.020 |
Why?
|
Child, Preschool | 2 | 2023 | 42056 | 0.020 |
Why?
|
Gene Expression | 2 | 2016 | 7587 | 0.020 |
Why?
|
Proteins | 1 | 2002 | 6029 | 0.020 |
Why?
|
Visual Field Tests | 1 | 2009 | 411 | 0.020 |
Why?
|
Abortion, Spontaneous | 1 | 2012 | 530 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4742 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3602 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2016 | 2145 | 0.020 |
Why?
|
Risk Assessment | 1 | 2008 | 24102 | 0.020 |
Why?
|
Blood Pressure | 1 | 2002 | 8525 | 0.020 |
Why?
|
Cyclic GMP | 1 | 2007 | 395 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2002 | 3763 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10553 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2852 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 7022 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3465 | 0.010 |
Why?
|
Immunotherapy | 1 | 2020 | 4642 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1974 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2897 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13505 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 1660 | 0.010 |
Why?
|
Keto Acids | 1 | 2002 | 34 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5797 | 0.010 |
Why?
|
Labetalol | 1 | 2002 | 29 | 0.010 |
Why?
|
Secretory Vesicles | 1 | 2003 | 128 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8311 | 0.010 |
Why?
|
Paraneoplastic Syndromes | 1 | 2003 | 155 | 0.010 |
Why?
|
Nitrous Oxide | 1 | 2002 | 166 | 0.010 |
Why?
|
Leucine | 1 | 2002 | 547 | 0.010 |
Why?
|
Hedgehog Proteins | 1 | 2005 | 769 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4372 | 0.010 |
Why?
|
Aging | 1 | 2019 | 8652 | 0.010 |
Why?
|
Karyotyping | 1 | 2002 | 1172 | 0.010 |
Why?
|
Cause of Death | 1 | 2011 | 3725 | 0.010 |
Why?
|
Drainage | 1 | 2006 | 1161 | 0.010 |
Why?
|
Glutamine | 1 | 2002 | 576 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 2558 | 0.010 |
Why?
|
Isoflurane | 1 | 2002 | 384 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2007 | 2141 | 0.010 |
Why?
|
Gene Amplification | 1 | 2002 | 1085 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2007 | 3215 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5877 | 0.010 |
Why?
|
Anesthetics, Inhalation | 1 | 2002 | 574 | 0.010 |
Why?
|
Survival Rate | 1 | 2011 | 12810 | 0.010 |
Why?
|
Amino Acids | 1 | 2002 | 1714 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23709 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2005 | 2825 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2002 | 2505 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4356 | 0.010 |
Why?
|
Respiration | 1 | 2002 | 1654 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2007 | 3839 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4571 | 0.010 |
Why?
|
Body Composition | 1 | 2002 | 2419 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2002 | 2061 | 0.010 |
Why?
|
Pregnancy | 1 | 2012 | 29746 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2005 | 11152 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16932 | 0.000 |
Why?
|
Insulin Resistance | 1 | 2002 | 3959 | 0.000 |
Why?
|
Membrane Proteins | 1 | 2005 | 7850 | 0.000 |
Why?
|